temozolomide has been researched along with ACTH-Producing Pituitary Adenoma in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Crooke's cell adenoma (CCA) is an aggressive subtype of corticotroph adenoma; however, CCA is associated with a high incidence of low expression of methyl guanine methyl transferase (MGMT), suggesting that temozolomide (TMZ) treatment might be effective for this tumor type." | 7.91 | Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. ( Inoshita, N; Kanazawa, I; Kurosaki, M; Morita, M; Oki, Y; Sugimoto, T; Takeno, A; Tanaka, S; Yamada, S; Yamaguchi, T; Yamamoto, M, 2019) |
| "To date only 18 patients with aggressive pituitary tumors or carcinomas treated with temozolomide have been reported." | 7.76 | Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. ( Assaker, R; Bernier, M; Borson-Chazot, F; Brue, T; Caron, P; Chabre, O; Chanson, P; Cornélius, A; Cortet-Rudelli, C; de Fraipont, F; Dufour, H; Figarella-Branger, D; François, P; Gaillard, S; Jouanneau, E; Muller, M; Passagia, JG; Raverot, G; Salenave, S; Sturm, N; Trouillas, J, 2010) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 6.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| " Targeting dopamine and somatostatin receptors on corticotroph adenomas with cabergoline or pasireotide, or both, controls cortisol production in up to 40% of patients." | 5.01 | Advances in the medical treatment of Cushing's syndrome. ( Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R, 2019) |
| " Recent evidence suggests that temozolomide (TMZ), an orally-active alkylating agent used principally in the management of glioblastoma, may also be effective in controlling aggressive/invasive pituitary adenomas/carcinomas." | 4.88 | Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. ( Annamalai, AK; Antoun, NM; Burnet, NG; Burton, H; Cheow, HK; Dean, AF; Gurnell, M; Halsall, DJ; Jefferies, SJ; Kandasamy, N; Kirollos, RW; Kovacs, K; Pickard, JD; Shaw, AS; Simpson, HL, 2012) |
| "Crooke's cell adenoma (CCA) is an aggressive subtype of corticotroph adenoma; however, CCA is associated with a high incidence of low expression of methyl guanine methyl transferase (MGMT), suggesting that temozolomide (TMZ) treatment might be effective for this tumor type." | 3.91 | Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. ( Inoshita, N; Kanazawa, I; Kurosaki, M; Morita, M; Oki, Y; Sugimoto, T; Takeno, A; Tanaka, S; Yamada, S; Yamaguchi, T; Yamamoto, M, 2019) |
| "To date only 18 patients with aggressive pituitary tumors or carcinomas treated with temozolomide have been reported." | 3.76 | Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. ( Assaker, R; Bernier, M; Borson-Chazot, F; Brue, T; Caron, P; Chabre, O; Chanson, P; Cornélius, A; Cortet-Rudelli, C; de Fraipont, F; Dufour, H; Figarella-Branger, D; François, P; Gaillard, S; Jouanneau, E; Muller, M; Passagia, JG; Raverot, G; Salenave, S; Sturm, N; Trouillas, J, 2010) |
| "Cushing's disease is a syndromic pathological condition caused by adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (ACTHomas) mediated by hypercortisolemia." | 2.72 | Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach. ( Fukuoka, H; Nakao, T; Ogawa, W; Yamamoto, M, 2021) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 2.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "Aggressive pituitary tumours causing Cushing's Disease are very rare, difficult to treat, and usually resistant to conventional therapy." | 2.58 | Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review. ( Gilis-Januszewska, A; Hubalewska-Dydejczyk, A; Kluczyński, Ł; Pach, D; Pantofliński, J; Sokołowski, G; Sowa-Staszczak, A; Turek-Jabrocka, R; Wilusz, M; Zieliński, G, 2018) |
| "Temozolomide (TMZ) is an oral alkylating agent that has been used over the past 8 years to treat aggressive pituitary tumors resistant to conventional therapy." | 1.43 | Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment. ( Aller, J; Campderá, M; Estrada, J; Lilienfeld, H; Magallón, R; Martín, P; Palacios, N; Saucedo, G, 2016) |
| "A 54-year-old man was diagnosed with Cushing's disease five years earlier on the basis of a typical clinical picture and hormonal tests." | 1.43 | Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment. ( Denew, P; Kurowska, M; Maksymowicz, M; Malicka, J; Tarach, JS; Zieliński, G, 2016) |
| "Temozolomide is an oral alkylating agent approved for glioblastoma multiforme treatment that has only recently shown promise in treating some pituitary tumors." | 1.37 | Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. ( Delashaw, JB; Dillard, TH; Fleseriu, M; Gultekin, SH; Neuwelt, EA; Yedinak, CG, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (88.89) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Lizzul, L | 1 |
| Lombardi, G | 1 |
| Barbot, M | 1 |
| Ceccato, F | 1 |
| Gardiman, MP | 1 |
| Regazzo, D | 1 |
| Bellu, L | 1 |
| Mazza, E | 1 |
| Losa, M | 1 |
| Scaroni, C | 1 |
| Yamamoto, M | 2 |
| Nakao, T | 1 |
| Ogawa, W | 1 |
| Fukuoka, H | 1 |
| Lasolle, H | 1 |
| Cortet, C | 1 |
| Castinetti, F | 1 |
| Cloix, L | 1 |
| Caron, P | 2 |
| Delemer, B | 1 |
| Desailloud, R | 1 |
| Jublanc, C | 1 |
| Lebrun-Frenay, C | 1 |
| Sadoul, JL | 1 |
| Taillandier, L | 1 |
| Batisse-Lignier, M | 1 |
| Bonnet, F | 1 |
| Bourcigaux, N | 1 |
| Bresson, D | 1 |
| Chabre, O | 2 |
| Chanson, P | 2 |
| Garcia, C | 1 |
| Haissaguerre, M | 1 |
| Reznik, Y | 1 |
| Borot, S | 1 |
| Villa, C | 1 |
| Vasiljevic, A | 1 |
| Gaillard, S | 2 |
| Jouanneau, E | 3 |
| Assié, G | 1 |
| Raverot, G | 3 |
| Gilis-Januszewska, A | 1 |
| Wilusz, M | 1 |
| Pantofliński, J | 1 |
| Turek-Jabrocka, R | 1 |
| Sokołowski, G | 1 |
| Sowa-Staszczak, A | 1 |
| Kluczyński, Ł | 1 |
| Pach, D | 1 |
| Zieliński, G | 2 |
| Hubalewska-Dydejczyk, A | 1 |
| Feelders, RA | 1 |
| Newell-Price, J | 1 |
| Pivonello, R | 1 |
| Nieman, LK | 1 |
| Hofland, LJ | 1 |
| Lacroix, A | 1 |
| Tanaka, S | 1 |
| Morita, M | 1 |
| Takeno, A | 1 |
| Kanazawa, I | 1 |
| Yamaguchi, T | 1 |
| Yamada, S | 1 |
| Inoshita, N | 1 |
| Oki, Y | 1 |
| Kurosaki, M | 1 |
| Sugimoto, T | 1 |
| Zacharia, BE | 1 |
| Gulati, AP | 1 |
| Bruce, JN | 2 |
| Carminucci, AS | 1 |
| Wardlaw, SL | 1 |
| Siegelin, M | 1 |
| Remotti, H | 1 |
| Lignelli, A | 1 |
| Fine, RL | 2 |
| Trouillas, J | 2 |
| Mendola, M | 1 |
| Passeri, E | 1 |
| Ambrosi, B | 1 |
| Corbetta, S | 1 |
| Bruno, OD | 1 |
| Juárez-Allen, L | 1 |
| Christiansen, SB | 1 |
| Danilowicz, K | 1 |
| Campderá, M | 1 |
| Palacios, N | 1 |
| Aller, J | 1 |
| Magallón, R | 1 |
| Martín, P | 1 |
| Saucedo, G | 1 |
| Lilienfeld, H | 1 |
| Estrada, J | 1 |
| Kurowska, M | 1 |
| Tarach, JS | 1 |
| Malicka, J | 1 |
| Maksymowicz, M | 1 |
| Denew, P | 1 |
| Thearle, MS | 1 |
| Freda, PU | 1 |
| Isaacson, SR | 1 |
| Lee, Y | 1 |
| Sturm, N | 1 |
| de Fraipont, F | 1 |
| Muller, M | 1 |
| Salenave, S | 1 |
| Cortet-Rudelli, C | 1 |
| Assaker, R | 1 |
| Dufour, H | 1 |
| François, P | 1 |
| Passagia, JG | 1 |
| Bernier, M | 1 |
| Cornélius, A | 1 |
| Figarella-Branger, D | 1 |
| Borson-Chazot, F | 1 |
| Brue, T | 1 |
| Dillard, TH | 1 |
| Gultekin, SH | 1 |
| Delashaw, JB | 1 |
| Yedinak, CG | 1 |
| Neuwelt, EA | 1 |
| Fleseriu, M | 1 |
| Salehi, F | 1 |
| Scheithauer, BW | 2 |
| Moyes, VJ | 1 |
| Drake, WM | 1 |
| Syro, LV | 2 |
| Manoranjan, B | 1 |
| Sharma, S | 1 |
| Horvath, E | 2 |
| Kovacs, K | 3 |
| Ortiz, LD | 1 |
| Ersen, A | 1 |
| Uribe, H | 1 |
| Fadul, CE | 1 |
| Rotondo, F | 1 |
| Annamalai, AK | 1 |
| Dean, AF | 1 |
| Kandasamy, N | 1 |
| Burton, H | 1 |
| Halsall, DJ | 1 |
| Shaw, AS | 1 |
| Antoun, NM | 1 |
| Cheow, HK | 1 |
| Kirollos, RW | 1 |
| Pickard, JD | 1 |
| Simpson, HL | 1 |
| Jefferies, SJ | 1 |
| Burnet, NG | 1 |
| Gurnell, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism[NCT05255900] | 20 participants (Anticipated) | Observational | 2022-04-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for temozolomide and ACTH-Producing Pituitary Adenoma
| Article | Year |
|---|---|
Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Carcinoma | 2020 |
Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Carcinoma; Dopamine Agonists | 2021 |
Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Out | 2018 |
Advances in the medical treatment of Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodi | 2019 |
Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Antineoplastic Agents, Alkyl | 2014 |
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dru | 2012 |
12 other studies available for temozolomide and ACTH-Producing Pituitary Adenoma
| Article | Year |
|---|---|
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Chemoradiothe | 2017 |
Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Combined Modality Therapy; D | 2019 |
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ca | 2014 |
Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cereb | 2014 |
Long-lasting complete remission after therapy with temozolomide in two patients with macrocorticotropinoma causing Cushing's disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Fe | 2015 |
Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Chemotherapy, A | 2016 |
Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Dacarbazine; Humans; Male; Middle Aged; Pituitary ACTH Hy | 2016 |
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitab | 2011 |
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; | 2010 |
Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
Topics: ACTH-Secreting Pituitary Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Midd | 2011 |
Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA | 2010 |
Anti-VEGF therapy in pituitary carcinoma.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, H | 2012 |